Invention Grant
- Patent Title: Ether linked triazoles as NRF2 activators
-
Application No.: US16468777Application Date: 2017-12-11
-
Publication No.: US11059816B2Publication Date: 2021-07-13
- Inventor: Anthony William James Cooper , Nicole Cathleen Goodwin , Charlotte Mary Griffiths-Jones , Thomas Daniel Heightman , Jeffrey K. Kerns , Hendrika Maria Gerarda Willems , Hongxing Yan
- Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED , ASTEX THERAPEUTICS LIMITED
- Applicant Address: GB Brentford; GB Cambridge
- Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED,ASTEX THERAPEUTICS LIMITED
- Current Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED,ASTEX THERAPEUTICS LIMITED
- Current Assignee Address: GB Brentford; GB Cambridge
- Agent Nora L. Stein; Fang Qian; Duke M. Fitch
- International Application: PCT/IB2017/057807 WO 20171211
- International Announcement: WO2018/109649 WO 20180621
- Main IPC: A61K31/553
- IPC: A61K31/553 ; A61P9/04 ; A61P11/00 ; C07D498/04 ; C07D419/12 ; C07D249/04 ; C07D401/12 ; C07D419/14 ; C07D513/04
Abstract:
The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof:
Public/Granted literature
- US20200071317A1 ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS Public/Granted day:2020-03-05
Information query
IPC分类:
